Galectin-1 is considered to be a regulator protein as it is ubiquitously expressed throughout the adult body and is responsible for a broad range of cellular regulatory functions. Interest in galectin-1 from a drug-design perspective is founded on evidence of its overexpression by many cancers and its immunomodulatory properties. The development of galectin-1-specific inhibitors is a rational approach to the fight against cancer because although galectin-1 induces a plethora of effects, null mice appear normal. X-ray crystallographic structure determination will aid the structure-based design of galectin-1 inhibitors. Here, the crystallization and preliminary diffraction analysis of human galectin-1 crystals generated under six different conditions is reported. X-ray diffraction data enabled the assignment of unit-cell parameters for crystals grown under two conditions, one belongs to a tetragonal crystal system and the other was determined as monoclinic P2 1 , representing two new crystal forms of human galectin-1.
Introduction
The carbohydrate moieties of glycoconjugates display enormous and unparalleled structural variability. Once thought of as simply energy stores and cell-structure constituents, emphasis is now placed on understanding how carbohydrate structure translates to function as the specific interplay between carbohydrates and proteins has been widely described to induce various cellular processes. Now thought of as molecules that transfer biological information, the complex array of structurally diverse carbohydrates has commonly been coined the 'sugar code' (Gabius et al., 2002 . The protein binding partners of the 'sugar code' are called lectins. Galectins are a type of lectin that are defined by a conserved carbohydrate-recognition domain (CRD) of $130 amino acids that has a specific affinity for glycoconjugates that contain -galactosides (Barondes et al., 1994) . Galectins are endogenous to a wide range of species and 15 mammalian galectins have currently been described. In short, galectins play numerous roles in regulating various cellular processes to achieve homeostasis. They act both extracellularly and intracellularly within most, if not all, tissues (Hernandez & Baum, 2002; Gray et al., 2005) . A high conservation of amino-acid sequence exists amongst mammalian galectins. Cattle, rats and humans exhibit above 85% sequence identity in galectin-1. Adult humans express galectin-1 within most tissues and galectin-1-induced activity has been linked to many effects, including apoptosis of thymocytes and T cells (Perillo et al., 1995; Nguyen et al., 2001; Matarrese et al., 2005) , differentiation of fibroblasts to the myogenic lineage (Goldring et al., 2002) , promotion of host-pathogen (HIV) interaction (Ouellet et al., 2005) and contradictory biphasic concentration-dependent mitogenic and cytostatic growth regulation (Adams et al., 1996; Scott & Zhang, 2002; Vas et al., 2005) . The overexpression of galectin-1 by many cancers also suggests that galectin-1 plays a role in tumorigenesis.
Although galectin-1 may have direct effects on tumorigenesis, protection from immune surveillance following lymphocyte apoptosis may also contribute to tumour proliferation (Scott & Weinberg, 2002;  van der Brule et al., 2004) . In accordance with galectin classification, in vitro galectin-1 is able to bind to glycoconjugates that contain -galactosides, but significantly only in the presence of a reducing agent such as -mercaptoethanol (-ME). The X-ray crystal structure of human galectin-1 reveals that when in the presence of -ME it is a non-covalently bound homodimer consisting of two 14.5 kDa subunits each comprised of antiparallel -strands that fold into asandwich structure (Lopez-Lucendo et al., 2004) . Each subunit possesses a -galactoside-binding site; these are positioned at opposing ends of the dimer (Lopez-Lucendo et al., 2004) . Considering this X-ray structure, the bivalent lectin ability of a dimeric form may mediate galectin-1 activity as it would enable the cross-linking of cells, via interaction with cell-surface -galactosides, (i) to each other, (ii) to the basal lamina or (iii) to the extracellular matrix, which would initiate downstream reaction pathways and ultimately achieve a phenotypic affect (Brewer, 2002) . However, this hypothesis can only be part of the picture, as lectin-independent activity has also been described for galectin-1. Non-lectin activity has been attributed to galectin-1-induced growth inhibition (Adams et al., 1996; Vas et al., 2005) , the interaction of galectin-1 with activated oncoprotein H-Ras12V (GTP bound; Paz et al., 2001; Prior et al., 2003) and the B-cell-specific transcriptional coactivator OCA-B (Yu et al., 2006) and also the interaction of galectin-1 with small synthetic peptides (Andre et al., 2005) . A non-lectin active site has been suggested to be located near the region of the dimeric interface (Adams et al., 1996; Scott & Zhang, 2002; Rotblat et al., 2004) , but a monomeric form has also been shown to be devoid of lectin activity and to act as a transforming growth regulator. Circular dichroism indicates the formation of disulfide bridges in the monomeric form, suggesting that a significant change in subunit structure occurs compared with that exhibited in the dimer (Yamaoka et al., 1996; Inagaki et al., 2000; Kadoya & Horie, 2005) . Currently, there is no knowledge of the location of the non-lectin active-site within this monomeric form and further investigation into which conformation of galectin-1 mediates which galectin-1 activity is required. Despite this ambiguity, a well documented positive correlation exists between reduced galectin-1 activity in vitro and inhibition of the carbohydrate-binding site (via addition of excess lactose) and has driven the production of -galactoside derivatives as a means of galectin-1-specific drug design in the fight against cancer.
A problem intrinsic to the design of carbohydrate-based drugs is that carbohydrate-protein interactions are notoriously weak. The K d of the disaccharide lactose binding to galectin-1 has been reported as 800 mM (Giguere, Patnam et al., 2006; . The multivalency of larger natural glycoconjugate ligands such as asialofetuin circumvent low affinity to some degree (Andre et al., 1999) . Chemically synthesized multivalent compounds in the form of linearly repeated lactose units (Di Virgilio et al., 1999) , larger wedgelike (Andre et al., 2001) and starburst (sugar-ball) glycodendrimers (Andre et al., 1999) and lactosamine derivatives composed of substitutions at non-critical hydroxyl groups (Ahmed et al., 1990; Andre et al., 1997) demonstrate variable degrees of increased affinity to galectin-1, but it is to be noted that increasing ligand size does not translate into linearly increasing affinity to galectin-1 (Andre et al., 1999) . Conversely, multivalent aglycon compounds have demonstrated K d values as low as 3.2 mM against galectin-1 (Giguere, Patnam et al., 2006; Tejler et al., 2006) . The development of potent galectin-1-specific therapeutics is a rational field of research in the fight against cancer and possibly HIV infection because galectin-1 knockout mice are fertile and appear normal (Poirier & Robertson, 1993; McGraw et al., 2005; Sakaguchi et al., 2006) .
In silico investigations of human and bovine galectin-1 and interactions with aglycon, trisaccharides and tetrasaccharides predict that part of these ligands extend outside the characterized galectin-1 carbohydrate-binding cleft. This suggests the importance of regions adjacent to this site that possibly could provide additional and/or alternative areas to be targeted in the advancement of the design of more potent and specific galectin-1 therapeutics, particularly utilizing modifications of ligands larger than glycoside disaccharides (Ford et al., 2003; . Asialofetuin, a large endogenous ligand of galectin-1, is a glycoprotein containing terminating triantennary glycosides that demonstrates variation in binding affinity to human galectin-1 across a pH range (Ahmed et al., 1990) . It has not yet been established for galectin-1 whether pH-induced structural rearrangements occur in the carbohydrate-binding site and/or adjacent regions that could be responsible for such variation. The crystal structure of wild-type human galectin-1 was obtained at pH 5.6 and several mutant structures have also been determined (Lopez-Lucendo et al., 2004) . Determination and subsequent analysis of further X-ray structures of human galectin-1 obtained under different crystallization conditions, along with comparison to the previous wild-type structure, will enable the assessment of structural differences arising from various conditions such as pH that may affect interaction with carbohydrates. This will provide further understanding of how the galectin-1 protein structure adapts and interacts with endogenous ligands in different environments.
Further understanding of the structural features that pertain to protein-ligand binding will advance galectin-1-specific inhibitor design and analysis of the X-ray crystal structures of human galectin-1 will be invaluable. Here we report the cloning, expression, purification, crystallization and preliminary diffraction analysis of human galectin-1 crystals grown under six novel conditions. Thses preliminary data provide new directions toward structural investigation of this protein that is important in cancer and immunology.
Experimental procedures and results
2.1. Cloning of human galectin-1 pProEX HTb-h-gal-1 encodes human galectin-1 fused to a hexahistidine tag and was extracted from h-gal-1 recombinant Escherichia coli DH5 cells (Scott & Zhang, 2002) . In order to facilitate crystallization, molecular biology techniques were utilized to generate non-tagged protein. The polymerase chain reaction (PCR) was used to amplify the human galectin-1 gene sequence, LGALS1, using pProEX HTb-h-gal-1 as the template, the forward primer 5 0 -CATATGGCTTGTGGTCTGGTCGCCAGC-3 0 (GeneWorks) and the reverse primer 5 0 -GGATCCTCAGTCAAAGGCCACACATTT-GATC-3 0 . The PCR product was ligated into the blunt-ended pCR-Blunt vector (Invitrogen), producing the pCR-Blunt-gal-1 plasmid. The primers engineered restriction-enzyme sites at regions flanking the LGALS1 gene sequence (bold). Digestion of pCR-Blunt-gal-1 plasmid with NdeI and BamHI restriction enzymes allowed stickyend ligation of LGALS1 into a similarly cut pET-3a vector (Novagen), thus yielding the pET-3a-gal-1 plasmid which encodes non-tagged human galectin-1. The integrity of the LGALS1 gene sequence inserted into the pET-3a vector was assessed by DNA sequencing.
Expression and purification of human galectin-1
E. coli strain BL21 DE3 was transformed with pET-3a-gal-1 plasmid for overexpression of human galectin-1. Recombinant E. coli BL21 DE3 cultures were grown at 303 K in Luria-Bertani (LB) medium supplemented with 100 mg ml À1 ampicillin. On reaching an OD 600 of approximately 0.5, the cultures were grown for a further 3 h and cells were then harvested by centrifugation at 6000g for 15 min and frozen. The expression system is not transcriptionally silent and so requires no inducer for optimal expression of target protein. A previous description of recombinant human galectin-1 purification (Lopez-Lucendo et al., 2004) served as a guide for the following methods. For cell lysis, frozen cell pellets were resuspended in 137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 pH 7.4 (PBS) supplemented with 4 mM -ME, 1 mM phenylmethylsulfonyl fluoride and 20 mg ml À1 DNaseI to reduce the viscosity upon lysis. The cells were lysed using hen egg-white lysozyme. Cell debris was removed by centrifugation at 20 000g for 30 min and the supernatant was filtered before being passed through a column of lactosylated Sepharose 4B (Levi & Teichberg, 1981) equilibrated in PBS supplemented with 4 mM -ME (PBS/-ME). The column was then washed with PBS/-ME to remove unbound material, followed by elution of the target protein with PBS/-ME supplemented with 100 mM lactose. The eluant was concentrated to $1 ml using Ultracel 5k concentrators (Amicon) and further purified by size-exclusion chromatography using Sephacryl S100 resin equilibrated in PBS/-ME supplemented with 5 mM lactose. Elution fractions exhibiting high galectin-1 purity were determined via SDS-PAGE analysis and then pooled for concentration and buffer exchange into 20 mM potassium/ sodium phosphate, 5 mM lactose, 4 mM -ME pH 7.0 ('crystallization buffer') using Ultracel 5k concentrators (Amicon). Bradford reagent was used to estimate the final protein concentration and SDS-PAGE analysis (Fig. 1 ) of 1 mg ml À1 human galectin-1 was then performed as a final check of purity. The non-covalently bound subunits of dimeric human galectin-1 disassociate under SDS-PAGE analysis to yield a band approximately 14.5 kDa in size (lane 2). The high purity of the human galectin-1 protein sample is corroborated by our dynamic light-scattering (DLS) results. Analysis of 10 mg ml À1 human galectin-1 in crystallization buffer (20 mM potassium/sodium phosphate, 5 mM lactose, 4 mM -ME pH 7.0) at 293 K using a CoolBatch 90 T instrument (Precision Detectors) reveals a reproducible single compact peak across 20 experiment repeats (Fig. 2) . The low polydispersity or 'spread' of the peaks (average polydispersity 25%) is indicative of a very homogeneous protein sample. The average hydrodynamic radius (R h ) is 1.88 nm, representing the dimeric (the calculated radius of gyration is 1.98 nm; that of the monomer is 1.38 nm) form of human galectin-1.
Crystallization of human galectin-1
Human galectin-1 in the presence of lactose (ligand) and -ME was crystallized under six different conditions via hanging-drop vapour diffusion at 295 K using 24-well plates (0.5 ml reservoir solution; crystals A-F; Fig. 3 ). Crystals A-E were obtained within days and crystal F within three months from drops containing 1 ml protein solution (galectin-1 at a concentration of 10 mg ml À1 in crystallization buffer) and 1 ml reservoir solution as listed in Table 1 . Except for crystal A (Fig. 3a) , all crystals were reproducible.
X-ray diffraction analysis
The protein nature of the crystals grown under all six new conditions has been demonstrated via X-ray diffraction analysis. Data from crystals grown under two conditions enabled the determination of unit-cell parameters and for one of these enabled determination of the structure by molecular replacement; refinement is in progress of this new crystal structure of human galectin-1. Conditions are currently being further optimized; here, we report the preliminary findings. Crystals A and B (Figs. 3a and 3b) were mounted in quartz capillaries (0.7-1.0 mm in diameter) and tested for X-ray diffraction at 295 K using a Bruker SMART 6000 diffractometer equipped with a SMART 6000 CCD detector and a MacScience M06X CE rotatinganode generator (Cu K; = 1.5418 Å ). Crystal A (Fig. 3a) cracked during loading into the capillary; the largest fragment diffracted to 2.4 Å but decayed significantly after 20 min. The fragile hexagonalshaped crystal B (Fig. 3b ) diffracted to only 3.5 Å , with the diffraction pattern indicating internal crystal disorder. Under higher pH conditions (pH 6.5) thin plate-like crystals were produced (Table 1 , crystal C; Fig. 3c ). One crystal was dipped in cryoprotectant solution comprising 30% PEG 8000, 0.1 M sodium cacodylate pH 6.5, 0.2 M ammonium sulfate, 1% -ME, 15% glycerol and flash-frozen using liquid N 2 prior to X-ray diffraction analysis at beamline 8.3.1 at the Advanced Light Source synchrotron (California, USA; wavelength 1.1159 Å at 100 K) using an ADSC CCD detector. Crystal C diffracted to 3 Å ; the diffraction data (frames with 1 ' oscillation range and with 1 s exposure) showed high mosaicity and the unit-cell parameters and crystal system were ambiguous. The clustered platelike crystal D, indicated by an arrow in Fig. 3(d) , was dipped in cryoprotectant solution comprising 20% PEG 8000, 0.1 M sodium cacodylate pH 6.5, 0.2 M magnesium acetate, 1% -ME, 20% glycerol and flash-frozen with liquid N 2 . X-ray diffraction quality was analysed at 100 K at beamline BL9-2 at the Stanford Synchrotron Radiation Laboratory (SSRL, California, USA; wavelength 0.97946 Å ) using a MAR325 CCD detector. Crystal D diffracted to 2.7 Å ; the pattern was anisotropic, with very weak diffraction exhibited along one axis, and the unit-cell parameters are currently undetermined. The small cube-like crystal E (Fig. 3e) Dynamic light-scattering analysis of a 10 mg ml À1 human galectin-1 protein sample under reducing conditions and in the presence of lactose. A single 'compact' peak is reproduced throughout 20 experimental repeats. Shown here is a peak from one experiment. The average of 20 repeats reveals a homogeneous protein sample of dimeric human galectin-1 that has a hydrodynamic radius (R h ) of 1.88 nm (calculated radius of gyration is 1.98 nm). comprising 20% PEG 550, 0.1 M MES pH 6.0, 0.01 M ZnSO 4 , 1% -ME, 5% glycerol and flash-frozen with liquid N 2 before X-ray diffraction analysis at SSRL BL9-2. Crystal E diffracted anisotropically to a maximum resolution of 2.8 Å . Data were collected (frames with 0.5 ' oscillation and 20 s exposure time), indexed and processed using MOSFLM (Leslie, 1992) and scaled using SCALA (CCP4 suite; Collaborative Computational Project, Number 4, 1994) , giving a data set that was complete to 3.9 Å resolution (Table 2) . Crystal E represents a new crystal form of human galectin-1 that belongs to a tetragonal crystal system, with unit-cell parameters a = b = 113.5, c = 62.6 Å . Further optimization of this crystallization condition is in progress. Crystal F (Fig. 3f ) was tested for X-ray diffraction at 295 K using our in-house X-ray source (described above for crystals A and B). Crystal F diffracted to a maximum resolution of 2.0 Å . Data were collected (frames with 0.3 ' oscillations and 60 s exposure time), indexed and processed using MOSFLM (Leslie, 1992) and scaled using SCALA (CCP4 suite; Collaborative Computational Project, Number 4, 1994) , giving a data set that was complete to 2.4 Å resolution ( (Navaza, 1994) , a clear molecular-replacement solution in space group P2 1 was determined. Refinement of this new crystal structure is ongoing for its ultimate use in in silico structure-based drug design of novel human galectin-1 inhibitors.
The role of galectin-1 in severe human ailments is well established and the consequent need for the development of potent specific galectin-1 inhibitors is recognized as becoming more urgent. Currently, one X-ray structure of wild-type human galectin-1 and two mutant galectin-1 structures (with a number of different ligands bound) are available for in silico structure-based drug design (Lopez-Lucendo et al., 2004) . We focus on generating further X-ray crystallo- 
Figure 3
Human galectin-1 co-crystallized with lactose in the presence of -ME. Crystals A-F shown in (a)-(f) were produced via hanging-drop vapour diffusion at 295 K. The scale bar represents 0.5 mm (all photographs are on the same scale). graphic structures of wild-type human galectin-1 obtained under conditions that differ from those reported, incorporating variations in pH, and also structures determined under different crystal systems. These will provide valuable insight into the ability of this protein to interact with both endogenous receptors as well as small molecules, providing unique structural information that can be utilized for structure-based drug design.
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